Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Avai Bio (AVAI) EBITDA (2018 - 2025)

Avai Bio's EBITDA history spans 6 years, with the latest figure at -$303432.0 for Q1 2024.

  • On a quarterly basis, EBITDA rose 71.69% to -$303432.0 in Q1 2024 year-over-year; TTM through Mar 2024 was -$2.1 million, a 151.02% decrease, with the full-year FY2025 number at -$1.1 million, up 46.34% from a year prior.
  • EBITDA hit -$303432.0 in Q1 2024 for Avai Bio, up from -$1.0 million in the prior quarter.
  • Over the last five years, EBITDA for AVAI hit a ceiling of $431541.0 in Q4 2020 and a floor of -$1.1 million in Q1 2023.
  • Historically, EBITDA has averaged -$250273.4 across 4 years, with a median of -$169819.0 in 2020.
  • The widest YoY moves for EBITDA: up 21950.18% in 2020, down 1866.77% in 2020.
  • Tracing AVAI's EBITDA over 4 years: stood at $431541.0 in 2020, then tumbled by 74.4% to $110471.0 in 2022, then plummeted by 1017.8% to -$1.0 million in 2023, then skyrocketed by 70.07% to -$303432.0 in 2024.
  • Business Quant data shows EBITDA for AVAI at -$303432.0 in Q1 2024, -$1.0 million in Q4 2023, and -$399621.0 in Q3 2023.